REFERENCES
2. Manzano-Nunez R, Rivera-Esteban J, Navarro J, et al. Uncovering the NAFLD burden in people living with HIV from high- and middle-income nations: a meta-analysis with a data gap from Subsaharan Africa. J Int AIDS Soc. 2023;26:e26072.
3. Spearman CW, Abdo A, Ambali A, et al. ; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Health-care provision and policy for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2021;6:1047-56.
4. Liu C, Zhu S, Zhang J, et al. Global, regional, and national burden of liver cancer due to non-alcoholic steatohepatitis, 1990-2019: a decomposition and age-period-cohort analysis. J Gastroenterol. 2023;58:1222-36.
5. Kilonzo SB, Kamala E, Jaka H, Ngoya P. Non-alcoholic fatty liver disease in Tanzania: prevalence, determinants, and diagnostic performance of triglycerides-glucose index and triglycerides-glucose index -body mass index compared to the hepatic ultrasound in overweight and obese individuals. BMC Gastroenterol. 2024;24:96.
6. Jeremiah K, Filteau S, Faurholt-Jepsen D, et al. Diabetes prevalence by HbA1c and oral glucose tolerance test among HIV-infected and uninfected Tanzanian adults. PLoS One. 2020;15:e0230723.
7. International Diabetes Federation. Tanzania country profile 2024. Available from: https://idf.org/our-network/regions-and-members/africa/members/tanzania/. [Last accessed on 10 Jul 2026].
8. Institute for Health Metrics and Evaluation. GBD compare 2017. Available from: https://vizhub.healthdata.org/gbd-compare/. [Last accessed on 10 Jul 2026].
9. Sterling RK, Lissen E, Clumeck N, et al. ; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-25.
10. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542.
11. Gattu AK, Fourman LT. Metabolic dysfunction-associated steatotic liver disease in people with HIV. Curr Opin HIV AIDS. 2025;20:350-8.
12. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389-97.e10.
13. van Kleef LA, Francque SM, Prieto-Ortiz JE, et al. Metabolic dysfunction-associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction. Gastroenterology. 2024;167:357-67.e9.
14. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-54.
15. Liu S, Chen X, Jiang X, et al. LiverRisk score: an accurate, cost-effective tool to predict fibrosis, liver-related, and diabetes-related mortality in the general population. Med. 2024;5:570-82.e4.
16. Strandberg R, Åberg F, Asteljoki JV, et al. Use of new CORE risk score to predict 10 year risk of liver cirrhosis in general population: population based cohort study. BMJ. 2025;390:e083182.
17. Ravichandran N, Broughan J, Mccombe G, et al. Process evaluation of a metformin RCT for people living with HIV with pre-diabetes in tanzania (META Trial): a study protocol. HRB Open Res. 2025;8:109.
18. US. Department of Health and Human Services, National Institute of Allergy and Infectious Diseases. DAIDS table for grading the severity of adult and pediatric adverse events, corrected version 2.1 2017. Available from: https://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-tables. [Last accessed on 10 Jul 2026].
19. Strandberg R, Shang Y, Ekstedt M, Vessby J, Hagström H. Validating non-invasive tests for diagnostic prediction of fibrosis in patients with biopsy-proven MASLD: CORE, LiverRisk, and FIB-4. EASL Congress, Amsterdam: 2025. Available from: https://www.postersessiononline.eu/173580348_eu/congresos/EASL2025/aula/-WED_477_EASL2025.pdf. [Last accessed on 10 Jul 2026].
20. Serra-Burriel M, Juanola A, Serra-Burriel F, et al. ; LiverScreen Consortium Investigators. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. Lancet. 2023;402:988-96.
21. GitHub - rickstra/. CORE: The Cirrhosis Outcome Risk Estimator for the 10 year risk of cirrhosis in primary care n.d. Available from: https://github.com/rickstra/CORE. [Last accessed on 10 Jul 2026].
22. Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:3-10.
23. Semmler G, Thöne P, Embacher J, et al. Prevalence of fibrosis and applicability of lab-based noninvasive tests from primary to tertiary care. Clin Gastroenterol Hepatol. 2025;Epub ahead of print.
24. Han JW, Kim HY, Yu JH, et al. Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis. Clin Mol Hepatol. 2024;30:S147-58.
25. Kjaergaard M, Lindvig KP, Thorhauge KH, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 2023;79:277-86.
26. Yendewa GA, Khazan A, Jacobson JM. Risk stratification of advanced fibrosis in patients with human immunodeficiency virus and hepatic steatosis using the fibrosis-4, nonalcoholic fatty liver disease fibrosis, and BARD scores. Open Forum Infect Dis. 2024;11:ofae014.
27. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13:221-62.
28. Abeysekera KWM, Fernandes GS, Hammerton G, et al. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study. Lancet Gastroenterol Hepatol. 2020;5:295-305.
29. Otto AO, Rivera CG, Zeuli JD, Temesgen Z. Hepatotoxicity of contemporary antiretroviral drugs: a review and evaluation of published clinical data. Cells. 2021;10:1263.
30. Capeau J, Lagathu C, Béréziat V. Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV. Curr Opin HIV AIDS. 2024;19:14-20.
31. Quesada-López T, Cereijo R, Blasco-Roset A, et al. Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function. Biochem Pharmacol. 2024;220:116010.
